Alphatec Holdings, Inc., a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. The company manufactures and sells implants, instruments, imaging equipment, and spare parts. It offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; SafeOp Neural InformatiX System that automates electromyographic, somatosensory evoked potential, and motor evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems. It also provides split-blade retractors; Sigma-ALIF Access System, a procedure-specific access system; spinal implants and fixation systems comprising NanoTec and Invictus, as well as various standalone implants for height restoration and stabilization. In addition, the company provides biologics comprising 3D ProFuse Osteoconductive Bioscaffold; AlphaGRAFT Demineralized Bone Matrix (DBM) comprising demineralized human tissue; BioCORE Moldable Bioactive Graft, a synthetic mineral-collagen composite matrix that can be molded to fit the bone defect; AlphaGRAFT DBM Fibers comprising demineralized fibers; AlphaGRAFT Cellular Bone Matrix (CBM), a growth factor-enriched cellular bone matrix; AlphaGRAFT CBM that is delivered in granular, fiber, or structural form; and Amnioshield Amniotic Tissue Barrier, an allograft for spinal surgical barrier applications. The company sells its products through a network of independent sales agents and direct sales representatives. The company was founded in 1990 and is headquartered in Carlsbad, California.…
ATEC Announces Participation in Upcoming Investor Conferences
Alphatec Holdings (NASDAQ: ATEC) is listed on Nasdaq, where its shares trade in USD. It belongs to the Medical Devices industry, part of the Healthcare sector, and reports about 913 employees.
The shares were at 6.680 USD on 20 November 2026, down 66.3% over 52 weeks. Its 52-week range is 6.630 USD to 23.29 USD, and it trades at the bottom of that range.
Its market capitalisation is 1.02B USD.
Alphatec Holdings reports an operating margin of -3.0% and revenue up 12.6% year over year.
Its debt exceeds its cash by 514.01M USD. Its Piotroski F-score is 6 out of 9, an average reading of its financial health. 14 analysts cover the stock, with an average rating of Buy; their mean price target of 12.93 USD is 93.5% above the current price. The next earnings report is expected on 24 February 2027.